A. Vogel Saw Palmetto Capsules

Here, we look at Prostasan (A. Vogel Saw Palmetto Capsules) with an evidence‑first lens: what LUTS/BPH actually are, how saw palmetto might work, what the clinical data say (especially for this extract type), a short note on tradition, and the safety guardrails.

The condition in plain terms

• What’s going on: Lower urinary tract symptoms (LUTS) in men—weak or intermittent stream, hesitancy, straining, incomplete emptying; plus storage symptoms such as urgency, frequency and night‑time urination—are commonly caused by benign prostatic hyperplasia (BPH), a non‑cancerous enlargement of the prostate. Other causes exist (e.g., infection, prostatitis, neurological disease, even cancer), which is why diagnosis matters. 【NICE overview of LUTS and common symptoms/causes. (nice.org.uk)】

What this product is allowed to claim (UK)

• Regulatory status: Prostasan holds a UK Traditional Herbal Registration, THR 13668/0011. The permitted indication is relief of lower urinary tract symptoms in men with a confirmed diagnosis of BPH—“based on traditional use only.” One soft capsule daily provides 320 mg of a saw palmetto fruit soft extract (9–12:1; extraction solvent ethanol 96% v/v). The SmPC/PIL reiterates: men 18+ with a doctor’s diagnosis of BPH; follow the leaflet. 【Product composition/THR number and indication. (bhma.info)】

How it might work: the compounds and plausible mechanisms

• The lipophilic extract is rich in free fatty acids (lauric, oleic, myristic, linoleic) and phytosterols. In vitro, these fatty acids inhibit 5‑α‑reductase (the enzyme that converts testosterone to DHT), and show binding activity at α1‑adrenergic and muscarinic receptors—mechanisms that could ease voiding symptoms. Anti‑inflammatory actions (e.g., effects on COX/5‑LOX/NF‑κB) are also reported. Mechanistic data are preclinical but biologically plausible. 【Mechanism summaries and fatty‑acid studies. (ema.europa.eu)】

What high‑quality evidence shows (and where it’s mixed)

• The EMA’s herbal committee (HMPC) distinguishes between extract types:
  • Hexane extracts: “well‑established use” for symptomatic treatment of BPH, supported by bibliographic clinical data (including trials vs finasteride/tamsulosin up to 1 year). 【HMPC conclusion for hexane extracts. (ema.europa.eu)】
  • Ethanol extracts (like Prostasan): recognised for “traditional use” only—clinically plausible, but studies have been small/short and not definitive. 【HMPC conclusion for ethanol extracts. (ema.europa.eu)】
• Independent systematic reviews: The Cochrane review updated to September 16, 2022, concludes that saw palmetto, when used alone, makes little to no difference to urinary symptoms or quality of life versus placebo at 3–6 months (and similarly at 12–17 months). A 2024 clinical summary reaches the same conclusion. These analyses pooled different brands and extract types (and even when hexane products were analysed separately, benefits were not clearly different). This aligns with the HMPC’s more conservative stance for ethanol extracts. 【Cochrane update and summary. (cochrane.org)】
• Practical read for you: for men with diagnosed BPH, an ethanolic saw palmetto product like Prostasan may feel helpful to some, but on average the evidence suggests modest-to‑no clinically meaningful improvement compared with placebo. Expectation‑setting is key. 【Cochrane perspective and HMPC summary, integrated. (cochrane.org)】

A very brief traditional backdrop

• Saw palmetto (Serenoa repens) berries have long use in North America for urinary/genital complaints; European use later focused on male urinary symptoms. Modern EU/UK registrations codify this as “traditional use” (for ethanol extracts) while reserving “well‑established use” for specific hexane extracts. 【Historical context and HMPC framing. (nccih.nih.gov)】

Are the marketing lines accurate?

• “Licensed for the relief of urinary symptoms in men with confirmed BPH.” In UK terms this is a THR‑registered traditional herbal medicine, not a fully licensed medicine. The permitted wording is relief of LUTS in men with confirmed BPH, based on traditional use only. The one‑capsule‑daily dose and ethanolic extract details are consistent with the PIL. 【Regulatory nuance and PIL detail. (bhma.info)】

Safety notes (the guardrails)

• Common, usually mild: belching, GI discomfort, headache; rare allergy. 【PIL/SmPC. (patient-info.co.uk)】
• Bleeding risk (rare, but important): case reports describe intraoperative haemorrhage and coagulopathy; peri‑operative guidance often advises stopping herbal supplements pre‑surgery as a precaution, and to use caution with anticoagulants/antiplatelets. Evidence is limited to case reports/observational data, but worth noting. 【Case reports and peri‑operative reviews. (pubmed.ncbi.nlm.nih.gov)】
• Liver: very rare, reversible liver injury has been reported; overall risk appears low. 【LiverTox review. (ncbi.nlm.nih.gov)】
• PSA and masking concerns: current evidence suggests saw palmetto does not lower PSA readings even at higher‑than‑usual doses (so it’s unlikely to “mask” PSA‑based monitoring), but men should still follow standard medical evaluation and follow‑up. 【NCCIH summary. (nccih.nih.gov)】
• Who should not use: women; under‑18s; anyone without a confirmed BPH diagnosis; and anyone with red‑flag symptoms (fever, chills, blood in urine, acute urinary retention) should seek medical care. 【PIL/SmPC guidance. (patient-info.co.uk)】

Bottom line for your curation

• Mechanism: plausible (5‑α‑reductase, receptor and anti‑inflammatory pathways), but mechanistic promise hasn’t consistently translated into clear clinical benefit for ethanolic extracts. 【Mechanism and HMPC conclusion. (pubmed.ncbi.nlm.nih.gov)】
• Evidence: for Prostasan’s extract type (ethanol), UK regulators classify it under “traditional use”; up‑to‑date systematic reviews find little‑to‑no symptom improvement vs placebo overall. 【Regulatory and Cochrane. (ema.europa.eu)】
• Fit with care: If a man already has a confirmed BPH diagnosis and prefers a plant‑based trial, a time‑boxed, reflective trial alongside guideline‑based care (fluid timing, bladder training, discussion of alpha‑blockers/5‑ARIs where appropriate) is reasonable—with a clear stop‑rule if nothing changes. 【NICE context for LUTS pathways. (nice.org.uk)】